Pmv Pharmaceuticals Inc (PMVP) - News Archive

The role of TP53 mutations in cancer has long been regarded as a critical factor in tumorigenesis and therapeutic resistance. With the advent of targeted therapies, the need for innovative approaches to treat malignanci...

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation PRINCETON, N.J., Sept. 10, 2025 PMV Pharmaceuticals, Inc. (...

PMV Pharmaceuticals, Inc. has provided an update on its financial performance and ongoing clinical endeavors regarding its lead oncology candidates. This article summarizes the second-quarter financial results for 2024...

The biopharmaceutical industry has witnessed a groundbreaking collaboration between Foundation Medicine, Inc., a leading molecular information company, and PMV Pharmaceuticals, Inc., an innovative precision oncology com...

PMV Pharmaceuticals: Bolstering Leadership for Late-Stage Development SuccessPMV Pharmaceuticals, a pioneering precision oncology company specializing in the development of small molecule therapies targeting p53, has re...